sumatriptan, Imitrex, Alsuma (cont.)
Omudhome Ogbru, PharmD
Omudhome Ogbru, PharmD
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Medical and Pharmacy Editor:
GENERIC AVAILABLE: Yes
PREPARATIONS: Tablets: 25, 50, 100 mg. Intranasal Solution: 5, 20 mg. Injection Solution: 4 and 6 mg/0.5 ml
STORAGE: Sumatriptan should be stored between 2-30 C (36-86 F).
PRESCRIBED FOR: All formulations of sumatriptan are used for acute treatment of migraine headaches with or without an aura in adults. The injectable formulation also is used for treating cluster headaches.
DOSING: The recommended oral dose is 25-100 mg and the maximum dose is 200 mg daily. The recommended intranasal dose is 5-20 mg and the maximum dose is 40 mg daily. The recommended injection dose is 4 or 6 mg injected under the skin. The maximum dose is two 6 mg injections separated by 1 hour.
DRUG INTERACTIONS: Monoamine oxidase inhibitors, for example, isocarboxazid (Marplan), phenelzine (Nardil), tranylcypromine (Parnate), and procarbazine (Matulane), may reduce the breakdown of sumatriptan in the liver, leading to increased blood levels and side effects of sumatriptan.
Combining sumatriptan with sibutramine (Meridia), selective serotonin reuptake inhibitors or SSRIs, including fluoxetine (Prozac), citalopram (Celexa), paroxetine (Paxil), and sertraline (Zoloft) or serotonin and norepinephrine reuptake inhibitors, including venlafaxine (Effexor), duloxetine (Cymbalta), and desvenlafaxine (Pristiq) may increase the concentration of serotonin in the brain, causing increased serotonin-related side effects.
Administering sumatriptan within 24 hours of treatment with an ergot-containing medication (dihydroergotamine [Migranal], ergotamine [Methergine]) is contraindicated because such combinations increase the likelihood of vasospasms.
PREGNANCY: Safe use in pregnancy has not been established.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Back to Medications Index